Clinical and computed tomography features (CT) of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) status

被引：0
|
作者：
Castanon Perez, Rosa Abril [1 ]
Gutierrez Herrero, Gustavo [1 ]
Alvarez Martinez, Haizea [1 ]
Lozano Cuesta, Pablo [1 ]
Sanchez Martin, Omar [1 ]
Arias Fuente, Maria [1 ]
Castallanos Romero, Lucia [1 ]
Rodriguez Pascual, Luis Carlos [1 ]
机构：
[1] Burgos Univ Hosp, Burgos, Spain
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Lung cancer;
D O I：
10.1183/13993003.congress-2020.1696
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1696
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Computed Tomography Morphological Classification of Lung Adenocarcinoma and Its Correlation with Epidermal Growth Factor Receptor Mutation Status: A Report of 1075 Cases
    Li, Qi
    He, Xiao-Qun
    Fan, Xiao
    Luo, Tian-You
    Huo, Ji-Wen
    Huang, Xing-Tao
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 3687 - 3698
  • [32] Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report
    Sun, Qiong
    Wu, Jian-Yu
    Jiao, Shun-Chang
    ONCOLOGY LETTERS, 2014, 8 (05) : 2093 - 2095
  • [33] Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung.
    Hussain, S
    Zakowski, MF
    Kris, MG
    Ladanyi, M
    Pao, W
    Riely, G
    Rizvi, N
    Gomez, JE
    Miller, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
  • [34] Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib
    Purkayastha, Abhishek
    Kapoor, Amul
    Singh, Harinder Pal
    Sarin, Arti
    Sengupta, Prasanta
    Singh, Sankalp
    Bisht, Niharika
    Husain, Azhar
    LUNG INDIA, 2018, 35 (06) : 527 - 529
  • [35] Prediction of epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma patients on computed tomography (CT) images using 3-dimensional (3D) convolutional neural network
    Zhang, Guojin
    Shang, Lan
    Cao, Yuntai
    Zhang, Jing
    Li, Shenglin
    Qian, Rong
    Liu, Huan
    Zhang, Zhuoli
    Pu, Hong
    Man, Qiong
    Kong, Weifang
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2024, 14 (08)
  • [36] Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung
    Fukui, Tomoya
    Tsuta, Koji
    Furuta, Koh
    Watanabe, Shun-ichi
    Asamura, Hisao
    Ohe, Yuichiro
    Maeshima, Akiko Miyagi
    Shibata, Tatsuhiro
    Masuda, Noriyuki
    Matsuno, Yoshihiro
    CANCER SCIENCE, 2007, 98 (11) : 1714 - 1719
  • [37] Anaplastic lymphoma kinase inhibitors/epidermal growth factor receptor antagonistsDevelopment of drug resistance in lung adenocarcinoma: 7 case reports
    Reactions Weekly, 2018, 1712 (1) : 78 - 78
  • [38] Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma
    Zhu, Pei
    Pan, Qingqing
    Wang, Mengzhao
    Zhong, Wei
    Zhao, Jing
    THORACIC CANCER, 2015, 6 (06) : 709 - 714
  • [39] A nomogram based on 18F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
    Guo, Yue
    Zhu, Hui
    Chen, Congxia
    Li, Xu
    Liu, Fugeng
    Yao, Zhiming
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2022, 12 (11) : 5239 - 5250
  • [40] Accurate prediction of epidermal growth factor receptor mutation status in early-stage lung adenocarcinoma, using radiomics and clinical features
    Zhu, Huiyuan
    Song, Yueqiang
    Huang, Zike
    Zhang, Lian
    Chen, Yanqing
    Tao, Guangyu
    She, Yunlang
    Sun, Xiwen
    Yu, Hong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 586 - 594
12345